This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.
In this video, you'll learn about
The phase 3 ICARIA-MM study of an anti-CD38 monoclonal antibody triplet regimen in relapsed and refractory multiple myeloma(RRMM) presented by Dr Ramasamy.
SARCLISA® + Pd demonstrated a 40% risk reduction in progression or death vs Pd (11.53 vs 6.47 months [absolute change 5 months]; HR 0.596, 95% CI: 0.44, 0.81; p=0.001).1
Relapsed Refractory Multiple Myeloma Product
Attal M, et al. Lancet. 2019;394:2096–107.
Date of Preparation: September 2023
▼This medicinal product is subject to additional monitoring.This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.